DE69127384T2 - Verfahren zur Reinigung von Immunserumglobulinen - Google Patents

Verfahren zur Reinigung von Immunserumglobulinen

Info

Publication number
DE69127384T2
DE69127384T2 DE69127384T DE69127384T DE69127384T2 DE 69127384 T2 DE69127384 T2 DE 69127384T2 DE 69127384 T DE69127384 T DE 69127384T DE 69127384 T DE69127384 T DE 69127384T DE 69127384 T2 DE69127384 T2 DE 69127384T2
Authority
DE
Germany
Prior art keywords
serum globulin
immune
immune serum
serum
globulins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69127384T
Other languages
English (en)
Other versions
DE69127384D1 (de
DE69127384T3 (de
Inventor
Maria Erlinda C Sarno
Gerald Neslund
Clifford Gaf
Sau-Gee Yung
James Burnham
Jean Kim
Rodolfo Anthony Vazquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23880046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69127384(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter International Inc filed Critical Baxter International Inc
Publication of DE69127384D1 publication Critical patent/DE69127384D1/de
Application granted granted Critical
Publication of DE69127384T2 publication Critical patent/DE69127384T2/de
Publication of DE69127384T3 publication Critical patent/DE69127384T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69127384T 1990-02-01 1991-01-31 Verfahren zur Reinigung von Immunserumglobulinen Expired - Lifetime DE69127384T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/473,559 US5177194A (en) 1990-02-01 1990-02-01 Process for purifying immune serum globulins
US473559 1990-02-01

Publications (3)

Publication Number Publication Date
DE69127384D1 DE69127384D1 (de) 1997-10-02
DE69127384T2 true DE69127384T2 (de) 1998-03-26
DE69127384T3 DE69127384T3 (de) 2004-05-19

Family

ID=23880046

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69127384T Expired - Lifetime DE69127384T3 (de) 1990-02-01 1991-01-31 Verfahren zur Reinigung von Immunserumglobulinen

Country Status (6)

Country Link
US (1) US5177194A (de)
EP (1) EP0440483B2 (de)
JP (1) JP3094167B2 (de)
AT (1) ATE157373T1 (de)
DE (1) DE69127384T3 (de)
ES (1) ES2108704T3 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5525519A (en) * 1992-01-07 1996-06-11 Middlesex Sciences, Inc. Method for isolating biomolecules from a biological sample with linear polymers
FR2706466B1 (fr) * 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
ATE175979T1 (de) * 1993-12-27 1999-02-15 Rotkreuzstiftung Zentrallab Verfahren zur herstellung eines konzentrates von anti-d-immunoglobulin g und pharmazeutische zusammensetzung, die dieses enthält
TW541179B (en) * 1997-03-19 2003-07-11 Green Cross Corp Process for preparing immunoglobulin preparation
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
IL121900A (en) * 1997-10-07 2001-12-23 Omrix Biopharmaceuticals Ltd A method for the purification of immunoglobulins
PT911037E (pt) * 1997-10-23 2002-12-31 Mitsubishi Pharma Corp Preparacao de imunoglobulina armazenavel a temperatura ambiente para injeccao intravenosa
UA64742C2 (uk) * 1997-12-24 2004-03-15 Альфа Терапевтик Корпорейшн СПОСІБ ОДЕРЖАННЯ РОЗЧИНУ <font face="Symbol">g</font>-ГЛОБУЛІНУ, ПРИЗНАЧЕНОГО ДЛЯ ВНУТРІШНЬОВЕННОГО ВВЕДЕННЯ, І ПРОДУКТ, ЩО ОДЕРЖУЄТЬСЯ У ЦЕЙ СПОСІБ (ВАРІАНТИ)
AU760048B2 (en) * 1998-05-06 2003-05-08 Genentech Inc. Protein purification by ion exchange chromatography
ES2527915T3 (es) * 1998-06-09 2015-02-02 Csl Behring Ag Producto de inmunoglobulina G (IgG) líquido
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
AU756832B2 (en) 1999-02-22 2003-01-23 Ncsrt, Inc. Purification of biological substances
DE19916352A1 (de) * 1999-04-12 2000-10-19 Braun Melsungen Ag Entfernung von hüllehaltigen Viren aus Blut, Plasma oder Serum
US6441144B1 (en) 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
KR100416483B1 (ko) * 2000-08-08 2004-01-31 주식회사 웰진 동물세포 배양용 혈청의 단계적 여과 시스템
US6962700B1 (en) 2000-09-13 2005-11-08 Atopix Pharmaceuticals Corporation Method of manufacturing immune globulin
ES2184594B1 (es) * 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
JP4317744B2 (ja) * 2001-05-30 2009-08-19 ナノキャリア株式会社 高分子化合物末端への導入物結合方法
US8420789B2 (en) 2002-09-11 2013-04-16 Chugai Seiyaku Kabushiki Kaisha Method for removing DNA contaminants from a protein-containing sample
EP1532983A1 (de) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulinpräparationen mit erhöhter Stabilität
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
TWI391399B (zh) 2005-05-25 2013-04-01 Hoffmann La Roche 測定溶離多肽之鹽濃度之方法
KR20080031684A (ko) 2005-06-14 2008-04-10 암젠 인코포레이티드 자가 - 완충성 단백질 제형
US7879332B2 (en) * 2005-09-01 2011-02-01 Plasma Technologies, Llc Ultra-high yield intravenous immune globulin preparation
US20070049732A1 (en) * 2005-09-01 2007-03-01 Zurlo Eugene J Ultra-high yield intravenous immune globulin preparation
US8293242B2 (en) * 2005-09-01 2012-10-23 Plasma Technologies, Llc Ultra-high yield of alpha-1-anti-trypsin
US20070128693A1 (en) * 2005-12-06 2007-06-07 Advantek Serum Laboratories Limited3/F Method for the inactivation and removal of dengue virus from biological samples
EP2522755B1 (de) 2007-08-13 2014-04-02 Baxter International Inc. IVIg-Modulation von Chemokinen zur Behandlung von Multipler Sklerose, Morbus Alzheimer und Morbus Parkinson
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
ES2406029T3 (es) 2008-04-15 2013-06-05 Grifols Therapeutics Inc. Ultrafiltración/diafiltración en dos fases
EA023382B1 (ru) 2009-05-27 2016-05-31 Бакстер Интернэшнл Инк. Способ получения высококонцентрированного препарата иммуноглобулина для подкожного применения
WO2010148117A1 (en) 2009-06-17 2010-12-23 Scantibodies Laboratory, Inc. Therapeutic and diagnostic affinity purified specific polyclonal antibodies
US8304524B2 (en) 2009-07-23 2012-11-06 Baxter International Inc. Manufacture of factor H (FH) and FH-derivatives from plasma
HUE028832T2 (en) 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
IT1397061B1 (it) * 2009-12-28 2012-12-28 Kedrion Spa Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale.
TR201903403T4 (tr) 2010-02-04 2019-04-22 Csl Behring Ag İmmünoglobulin preparatı.
EP2361636A1 (de) 2010-02-26 2011-08-31 CSL Behring AG Immunglobulinpräparat und Aufbewahrungssystem für ein Immunglobulinpräparat
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
CN103119058A (zh) 2010-07-23 2013-05-22 巴克斯特国际公司 由血浆生产间-α-抑制蛋白(IAIP)
EP4289445A3 (de) 2010-09-17 2024-02-21 Takeda Pharmaceutical Company Limited Stabilisierung von immunglobulinen anhand einer wässrigen formulierung mit histidin bei schwach sauren bis neutralem ph-wert
EP3395825B1 (de) 2010-12-16 2021-11-10 Takeda Pharmaceutical Company Limited Echtzeitüberwachung und steuerung von proteinproduktionsverfahren unter verwendung von impedanzspektroskopie
PL2734544T3 (pl) 2011-07-18 2021-05-31 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Sposoby i kompozycje do hamowania patologii związanej z poliomawirusem
EP2748193B1 (de) * 2011-08-26 2017-02-01 Baxalta GmbH Verfahren zur reduzierung des thromboembolischen potentials einer aus plasma gewonnenen immunoglobulinzusammensetzung
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
IL274512B1 (en) 2012-02-29 2024-03-01 Baxalta Inc IgG-stimulated remodeling of peripheral nerve myelin
AU2014350370B2 (en) * 2013-11-15 2017-04-13 Novartis Ag Removal of residual cell culture impurities
MX2018009331A (es) 2016-02-03 2018-11-09 Plasma Tech Llc Metodos para extraer proteinas a partir de un material a base de sangre.
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas
US10815270B1 (en) 2019-09-20 2020-10-27 Plasma Technologies, Llc Compositions and methods for high efficiency protein precipitation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869436A (en) * 1971-06-01 1975-03-04 Statens Bakteriologiska Lab Method for fractionating plasma proteins using peg and ion-exchangers
US3962421A (en) * 1973-06-18 1976-06-08 American Home Products Corporation Method for the disruption of lipid-containing viruses
US4315919A (en) * 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4314997A (en) * 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4719290A (en) * 1983-09-02 1988-01-12 Armour Pharmaceutical Corporation Composition of intravenous immune globulin
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
US4606825A (en) * 1985-04-22 1986-08-19 J. T. Baker Chemical Company Purification of immunoglobulin G
DE3640513A1 (de) * 1986-11-27 1988-06-09 Biotest Pharma Gmbh Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
DE3730533A1 (de) * 1987-09-11 1989-03-30 Biotest Pharma Gmbh Verfahren zur sterilisation von plasma oder plasmafraktionen

Also Published As

Publication number Publication date
JP3094167B2 (ja) 2000-10-03
DE69127384D1 (de) 1997-10-02
DE69127384T3 (de) 2004-05-19
EP0440483A3 (en) 1992-09-23
ES2108704T3 (es) 1998-01-01
EP0440483B1 (de) 1997-08-27
EP0440483A2 (de) 1991-08-07
US5177194A (en) 1993-01-05
EP0440483B2 (de) 2003-06-18
ATE157373T1 (de) 1997-09-15
JPH06136000A (ja) 1994-05-17

Similar Documents

Publication Publication Date Title
DE69127384T2 (de) Verfahren zur Reinigung von Immunserumglobulinen
Burnouf Chromatography in plasma fractionation: benefits and future trends
US5164487A (en) Manufacturing intravenous tolerable immunoglobulin-g preparation
KR970010923B1 (ko) 혈장단백질의 크로마토그래피 분리법
CZ287186B6 (en) Process for preparing concentrate free of aggregation of immunoglobulins G
IL158893A (en) Method for preparing human immunolobulin concentrates for therapeutic use, involving chromatography on an anion exchange at an alkaline ph
CA2527138A1 (en) Optimal placement of a robust solvent/detergent process post viral ultrafiltration on an immune gamma globulin
EP0094672B1 (de) Verfahren zur Reinigung von Human-Interferon
US5252217A (en) Blood coagulation factor XI concentrate having high specific activity, suitable for therapeutic use, and process for preparing same
DE69311337D1 (de) Verfahren zur Reinigung von Proteinen
GR3005037T3 (de)
AU2011364724B2 (en) Method for producing injectable formulations of blood-derived protein materials, and materials obtained using said method
US3808124A (en) Purification of human plasminogen
CN1105779C (zh) 一种从生物原料中制备因子ix的方法
UA44261C2 (uk) Спосіб одержання вітамін к-залежних протеїнів за допомогою методів мембранної хроматографії
US4696899A (en) Process for the preparation of human leukocyte and human gamma interferon
US20210363179A1 (en) Method for removing fxi when purifying plasma proteins
KR900015748A (ko) 안티트롬빈-ⅲ의 정제 방법 및 이 안티트롭빈-ⅲ를 함유한 안티트롬빈-ⅲ 제제
RU2148411C1 (ru) Способ получения с помощью хроматографических методов вирусно-инактивированной фракции, содержащей фактор viii
CA2022165A1 (en) Albumin purification
US5094949A (en) Use of chymotrypsin for the inactivation of prekallikrein activator
RU96110890A (ru) Способ получения с помощью хроматографических методов вирусно-инактивированной фракции, содержащей фактор viii
WO2023204377A1 (ko) 면역글로불린 정제방법
RU2082412C1 (ru) Способ выделения с4 компонента комплемента человека
KR950023726A (ko) 한국형 씨(c)형 간염 바이러스의 항원 결정부위 융합 단백질인 유비엔에스4 이 12-ii(ubns4e12-ii)의 정제방법

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings